
Trump's tariff threats are back. What should you do about your 401(k) and investments?
The 90-day 'pause' on sweeping U.S. tariffs was scheduled to end Wednesday, but Trump extended the deadline to Aug. 1. Fresh threats went out this week to more than 20 countries — including Japan, South Korea, Canada, Mexico and Brazil — as well as the European Union for reciprocal tariffs ranging from 20% to 50% starting that day. On Wednesday, Trump said a 50% tariff on copper would also take effect on that date.
The first time tariff threats were issued, in Trump's April 2 'Liberation Day' announcements, the markets reacted by plunging into bear territory. The S&P 500 lost 10%, Nasdaq was down 11%, and the Dow dipped 9.48%. And despite the Trump administration's firm messaging that the president would never back down on the tariffs, he did. A 90-day pause was announced, and an acronym was born on Wall Street: TACO, short for Trump Always Chickens Out.
The chaos also sowed widespread financial fear among Americans. Some investors panicked and sold when the market dropped. People at or nearing retirement worried they didn't have the horizon to ride out a prolonged down period.
The Chronicle asked experts at the time what people should do with their money, with their 401(k), and with their investments if they were already retired.
They all said the same thing: Stay the course. Each pointed out that market fluctuations are to be expected, and things always get back to normal, though it might take a while. In this case, it took very little time at all: The market losses were erased by the end of May.
A different picture this time
This time around, Wall Street doesn't appear to be taking the trade war too seriously, though markets bounced around a bit during the week.
There was a notable downturn of nearly 1% on major markets after the tariff letters went out Monday, but things quickly rebounded. Then a letter Trump sent to Canada late Thursday suggesting the country could face a higher 35% tariff led to another small downturn Friday: The Dow fell by more than 250 points and closed down 1.02% for the week; the S&P 500 was down .31% and the Nasdaq down .08% for the week, though both hit record highs on Thursday.
Overall, 'The market really seems to be shrugging this latest round of tariff threats off,' said Christine Benz, the director of personal finance and retirement planning for Morningstar. 'It seems to effectively be calling the president's bluff.'
Still, she added, that doesn't mean we're out of the woods.
'U.S. stocks are not cheap, and when that's the case, they can be vulnerable to whatever shock that comes along, whether tariffs, geopolitical uncertainty or signs that the economy is slowing down,' Benz said.
Historically speaking, the market always rebounds from those shocks. We just saw it happen in April. Back then, Matthew Chancey, a certified financial planner and the founder of Tax Alpha Companies, said some people experience a type of cognitive bias where they believe what they're experiencing is completely unique and no past patterns or rules apply — sometimes referred to in economics as the 'this time it's different' fallacy. People who said 'this is the end of the stock market forever' in April were wrong, and anyone who thinks this time around will be the definitive end of the American economy is probably wrong, too.
'The current administration has not articulated a consistent trade policy, and every position is only a compliment away from being reversed,' said Carlos Aguirre, a financial literacy and career development manager for San Mateo-based Peninsula Family Service. 'As a result, Wall Street seems to be tuning out the noise coming out of the White House.'
Should you be tuning it out, too? Or is this an opportunity to make some moves to protect yourself and your savings? Here's what experts say.
What should you do with your retirement and 401(k) right now?
The Chronicle went back to every expert and asked them what people should be doing with their money right now to prepare for tariffs 2.0. The overwhelming advice: Stay the course.
'Generally that's always the right thing to do, keep it steady and don't do anything crazy,' said Sam Nofzinger, the general manager of brokerage for investment platform Public. Like Benz, he said just because things seem calm right now doesn't mean they'll stay that way: 'I do think we are going into some much more uncertain times.'
On Public, he said he's observed some unusual investor activity over the past three months. More people have been searching for international stocks and crypto. He's seen more movement in diversified ETFs (investment funds that hold multiple assets like stocks, bonds and commodities) than traditional single stocks, and said for the first time in a decade he's seeing interest in international ETFs. And some people are opting to stash more in cash through high-yield savings accounts, reflecting uncertainty about the economy in the near term.
'What we're seeing, given the economy, people are a lot less confident in their job security than they may have been six to nine months ago,' he said. 'That's translating to higher emergency savings balances. People saving 12 months instead of six. I think we are seeing people get conservative because they're worried about their own situation.'
Another chance to 'buy the dip'?
In the post-Liberation Day downturn, some investors joked that it wasn't a stock market tumble — stocks were just on sale. If you put a little more money into the market then, what's known as 'buying the dip,' you probably saw a decent quick return.
'For folks that have a relatively good time horizon, any time the market is off 20% is a good time to buy,' Nofzinger said. But it could take years, not weeks or months, to see your return.
JL Collins, the author of 'The Simple Path to Wealth' (the most recent edition of which was published in May), said he's not a fan of the practice.
'Research indicates 'buying the dip,' while sounding good, is not all that useful,' he said. 'Better to set up automatic investments and then, when the market happens to be down, celebrate buying shares at bargain prices.'
Of course, it's always a good time to do a money check-in and revisit the fundamentals. If you did my Wealth Challenge back in January, we're now halfway through the year. (If you didn't, you can sign up at sfchronicle.com/wealthchallenge). Are your investments and savings automated? Do you have a budget for your house — not in your head, but written down somewhere? Is your emergency fund in good shape?
If you've got the basics down, there's no reason to sweat when politicians turn up the heat.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
HCA raises annual profit forecast on resilient demand for medical care
(Reuters) -HCA Healthcare raised its 2025 profit forecast on Friday as it expects sustained demand for medical procedures to cushion a hit from U.S. President Donald Trump's potential tariffs. Health insurers have flagged higher-than-anticipated costs in its individual plans that come under the Affordable Care Act, also known as Obamacare, and its Medicaid plans for low-income people. Analysts have said they expect this trend to benefit hospital operators, but warned that proposed federal budget cuts could hit their earnings. HCA earned second-quarter adjusted profit of $6.84 per share, beating analysts' estimates of $6.25 per share, according to data compiled by LSEG. The company expects 2025 profit to be about $25.50 to $27 per share, compared with its previous forecast of $24.05 to $25.85 per share. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. The titles of the poster presentations are listed below. #8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) #3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC) Abstracts will be published online via the ESMO website at 00:05 CEST on October 13th 2025 (6:05 pm ET on October 12th). Following the presentations, copies of the presentations will be posted on About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Safe Harbor This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell presenting clinical data presentations at the ESMO Congress 2025; and the contents of all such presentations are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@ Investor Relations Contact:investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
– Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission decision expected by Q4 2025 – CARLSBAD, Calif., July 25, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4 2025. "Building on the strong early launch of TRYNGOLZA in the U.S., the positive CHMP opinion advances our commitment to expand access to TRYNGOLZA globally," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "TRYNGOLZA has demonstrated significant reductions in triglycerides and substantial reductions in acute pancreatitis events with favorable safety and tolerability. With this robust clinical profile, combined with Sobi's deep commercial market expertise in FCS, TRYNGOLZA has the potential to make a meaningful difference for people living with FCS in the EU." The CHMP opinion is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA demonstrated a statistically significant reduction in triglyceride levels at six months that was sustained through 12 months. Additionally, TRYNGOLZA demonstrated a substantial and clinically meaningful reduction in acute pancreatitis events over 12 months. TRYNGOLZA showed a favorable safety and tolerability profile. Study results were published in The New England Journal of Medicine (NEJM). FCS is a rare and genetic form of severe hypertriglyceridemia (sHTG) that prevents the body from breaking down fats and severely impairs the ability to remove triglycerides from the bloodstream. People with FCS often have triglyceride levels of more than 880 mg/dL (10 mmol/L), compared to normal levels of <150 mg/dL (1.7 mmol/L), and are at high risk of developing acute pancreatitis, which can be life-threatening. In the EU, FCS is estimated to impact up to 13 people per million. Sobi has exclusive rights to commercialize TRYNGOLZA in countries outside the U.S., Canada and China. As Ionis' European commercial partner for Waylivra (volanesorsen), the only medicine currently approved for FCS in the EU, Sobi will leverage existing market expertise and distribution channels to enable an effective TRYNGOLZA launch in FCS, if approved. "The approval recommendation brings us one step closer toward delivering TRYNGOLZA to people living with FCS in the EU and is a testament to our long-standing support for the FCS community," said Lydia Abad-Franch, M.D., MBA, head of research, development and medical affairs and chief medical officer, Sobi. "Patients with FCS suffer from complications such as acute pancreatitis. These are very severe events, often requiring intensive care and sometimes causing multiorgan failure as well as increasing morbidity and mortality. We believe TRYNGOLZA has the potential to be an important treatment for people living with this rare and serious disease, and we look forward to the final decision from the EC later this year." TRYNGOLZA was approved in the United States in December 2024 and granted orphan designation in the EU. Olezarsen is also being evaluated for sHTG, a serious condition defined by dangerously high triglycerides (≥500 mg/dL), and data from the Phase 3 CORE and CORE2 studies are expected in Q3 2025. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. People living with FCS are at high risk of acute pancreatitis in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About TRYNGOLZA® (olezarsen) TRYNGOLZA® is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. TRYNGOLZA® (olezarsen) is approved in the United States as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). For more information about TRYNGOLZA, visit TRYNGOLZA is not yet approved for any indication in Europe. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, olezarsen, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® and TRYNGOLZA® are trademarks of Ionis Pharmaceuticals, Inc. View source version on Contacts Ionis Investor Contact: D. Wade Walke, 760-603-2331Ionis Media Contact: Hayley Soffermedia@ 760-603-4679 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data